ReviewEuropean journal of clinical pharmacology2008
Pharmacovigilance: methods, recent developments and future perspectives.
Review in European journal of clinical pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 4 syntheses or guidelines pooled it, 290 citations in OpenAlex.
- Factors associated with underreporting of adverse drug reactions by patients: a systematic review.International journal of clinical pharmacy · 2023Pooled it
- A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators.Therapeutic innovation & regulatory science · 2022Pooled it
- Intensive Monitoring Studies for Assessing Medicines: A Systematic Review.Frontiers in medicine · 2019Pooled it
- The value of patient reporting to the pharmacovigilance system: a systematic review.British journal of clinical pharmacology · 2017Pooled it
- Intensive monitoring of duloxetine: results of a web-based intensive monitoring study.European journal of clinical pharmacology · 2013Trial
- Large Language Models for World Health Organization-Uppsala Monitoring Centre Drug-Adverse Event Causality Assessment Using Food and Drug Administration Adverse Event Reporting System Cases: Comparative Performance Study.Journal of medical Internet research · 2026Article
- Innovating global regulatory frameworks for generative AI in medical devices is an urgent priority.NPJ digital medicine · 2026Review
- Revealing the Future of Pharmacovigilance in Precision Pharmaceutical Monitoring.Current drug safety · 2026Review
- Disproportionality analysis of GLP-1 receptor agonists combined with metformin based on the FAERS database.Scientific reports · 2025Article
- Analysis of the Recurrence of Adverse Drug Reactions in Pediatric Patients with Epilepsy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Promoting Patient Engagement in Adverse Drug Reaction Reporting: A Novel Approach Utilizing Set Induction-Based Skill Questionnaires.Current drug safety · 2025Article
- Transformer-based models for ADR detection: cross-drug validation and benchmarking against large language models.Therapeutic advances in drug safety · 2025Article
- Cancer-Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK Yellow Card Adverse Drug Reaction (ADR) Reporting.Cancers · 2024Article
- Comparative Analyses of the Safety Profiles of Vitamin D Receptor Agonists: A Pharmacovigilance Study Based on the EudraVigilance Database.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Causality, Severity, Preventability and Predictability Assessments Scales for Adverse Drug Reactions: A Review.Cureus · 2024Review
- Why Pharmacovigilance of Non-steroidal Anti-inflammatory Drugs is Important in India?Endocrine, metabolic & immune disorders drug targets · 2024Review
- Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety.Patient preference and adherence · 2024Review
- The American Program in Pharmacovigilance (Am2P): a new accredited online training program in pharmacovigilance and pharmacoepidemiology.Therapeutic advances in drug safety · 2024Article
- A discovery and verification approach to pharmacovigilance using electronic healthcare data.Frontiers in pharmacology · 2024Article
- Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis.Current drug safety · 2024Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmacovigilance, defined by the World Health Organisation as 'the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem' plays a key role in ensuring that patients receive safe drugs. Our knowledge of a drug's adverse reactions can be increased by various means, including spontaneous reporting, intensive monitoring and database studies. New processes, both at a regulatory and a scientific level, are being developed with the aim of strengthening pharmacovigilance. On a regulatory level, these include conditional approval and risk management plans; on a scientific level, transparency and increased patient involvement are two important elements.
objectiveTo review and discuss various aspects of pharmacovigilance, including new methodological developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.